Public Good Pharma develops low-cost, effective therapies by funding clinical trials through financial innovation with health insurers. The company designs and executes self-funding Interventional Pharmacoeconomic (IVPE) trials comparing expensive specialty drugs to lower-cost alternatives. This model reduces healthcare spending for payers while generating evidence for broader adoption of cost-effective treatments.
Funding
Funding not disclosed
Founders
Product
Problem
The escalating cost of specialty pharmaceuticals presents a significant challenge for health insurers, leading to reduced patient access and financial strain on healthcare systems. Traditional methods for evaluating cost-effectiveness often lag behind the rapid introduction of high-priced novel therapies.
Solution
Public Good Pharma (PGP) partners with health insurers to implement Interventional Pharmacoeconomic (IVPE) trials, a novel approach to cost containment. PGP designs and executes clinical trials focused on identifying and validating lower-cost alternatives to expensive specialty drugs, including repurposed generics, biosimilars, and optimized dosing regimens. By leveraging payer data and generating robust clinical evidence, PGP enables insurers to confidently reimburse more cost-effective therapies without assuming financial or legal risk. This model facilitates reduced pharmaceutical spend, improved patient access to necessary treatments, and fosters sustainable innovation within the pharmaceutical landscape.
Target Audience
PGP collaborates with forward-thinking payers, including self-insured employers, pass-through PBMs, state health plans, and integrated health systems.
Features
- Design and execution of Interventional Pharmacoeconomic (IVPE) trials
- Focus on cost-effective alternatives such as repurposed generics, biosimilars, dose de-escalations, and lifestyle interventions
- Generation of high-quality clinical evidence under regulatory and ethical oversight
- Payer-agnostic approach, allowing for unbiased evaluation of therapeutic options
- Alignment of incentives with patients and payers through revenue generation from reduced pharmaceutical spend
- Targeting of high-cost therapeutic areas, including oncology and cell & gene therapies
- Potential for FDA approval of cost-effective therapies